Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit

Die periphere arterielle Verschlusskrankheit ist eine häufige, chronische Störung der arteriellen Durchblutung vor allem der unteren Extremitäten mit Stenosen- und Thrombenbildung. Bei betroffenen Patienten liegt ein hohes Risiko für kardiovaskuläre Komplikationen vor. Daher besteht Optimierungsbedarf bei der antithrombotischen Therapie. Der Beitrag schildert die aktuelle Studienlage dazu, die den behandelnden Ärzten bekannt sein sollte.

Kernaussagen

• Die PAVK geht mit hohen Komplikationsraten an den Extremitäten sowie einer hohen systemischen kardiovaskulären Morbidität und Mortalität einher. Nach Eingriffen am arteriellen Gefäßsystem steigt die Häufigkeit kardiovaskulärer Ereignisse.

• Die Optimierung der antithrombotischen Therapie hat großes Potenzial. Zur Rolle der Mehrfach-Thrombozytenaggregationshemmung durch neue Arzneimittelklassen werden in den nächsten Jahren Studiendaten erwartet.

• Über die Thrombozytenaggregationshemmung hinaus zeigte die zusätzliche Hemmung der Gerinnungskaskade klinisch nicht mehr zu vernachlässigende Vorteile für Patienten mit PAVK – bei vertretbarem Sicherheitsprofil.

• Die Versorgung von Patienten mit PAVK erfordert sektorenübergreifende Planung und Kommunikation, um die Adhärenz der Patienten von ärztlicher und nicht ärztlicher Seite zu motivieren. Behandelnde Ärzte aller Versorgungsstufen sollten über die Therapieansätze bei der PAVK informiert sein.

Schlüsselwörter

PAVK - Atherosklerose - Risikomanagement - Thrombozytenaggregationshemmer - Antikoagulanzien

Publication History

Article published online:
28 July 2021

• Literatur

• 1 Jones WS, Patel MR. Antithrombotic therapy in peripheral artery disease: generating and translating evidence into practice. J Am Coll Cardiol 2018; 71: 352-362
• 2 Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004; 17: 51-61
• 3 Lawall H, Diehm C, Hoffmann U. et al. Update PAVK: epidemiology, comorbidity and prognosis of peripheral arterial obstructive disease. Dtsch Med Wochenschr 2015; 140: 1798-1802
• 4 Noronen K, Saarinen E, Albäck A. et al. Analysis of the elective treatment process for critical limb ischaemia with tissue loss: Diabetic patients require rapid revascularisation. Eur J Vasc Endovasc Surg 2017; 53: 206-213
• 5 Malyar N, Freisinger E, Reinecke H. Periphere arterielle Verschlusskrankheit – Entwicklungen zur Morbidität und Letalität in Deutschland. Dtsch Med Wochenschr 2018; 143: 766-770
• 6 Alahdab F, Wang AT, Elraiyah TA. et al. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. J Vasc Surg 2015; 61: 42S-53S
• 7 Dohmen A, Espinola-Klein C, Huppert P. et al. S3-Leitlinie PAVK. Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. S3-Leitlinie AWMF 065-003. VASA 2016; 45: 1-96
• 8 De Backer TL, Van der Stichele R, Lehert P. et al. Naftidrofuryl for intermittent claudication. Cochrane Database Sys Rev 2008; (02) CD001368
• 9 Bedenis R, Stewart M, Cleanthis M. et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014; (10) CD003748
• 10 Bendermacher BL, Willigendael EM, Teijink JA. et al. Medical management of peripheral arterial disease. J Thromb Haem 2005; 3: 1628-1637
• 11 Zhang Y, Hu G, Yuan Z. et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and metaanalysis. PloS One 2012; 7: e42551
• 12 Espinola-Klein C. Anti-thrombotic treatment of patients with peripheral artery disease (PAD). Dtsch Med Wochenschr 2018; 143: 1060-1064
• 13 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
• 14 Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Vasc Med 1998; 3: 257-260
• 15 Morrow DA, Braunwald E, Bonaca MP. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413
• 16 Bonaca MP, Scirica BM, Creager MA. et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013; 127: 1522-1529 1529e1–1529e6
• 17 Bonaca MP, Creager MA, Olin J. et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA2°P-TIMI 50 trial. JACC Cardiovasc Interv 2016; 9: 2157-2164
• 18 Tepe G, Bantleon R, Brechtel K. et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy – the MIRROR study: a randomised and doubleblinded clinical trial. Eur Radiol 2012; 22: 1998-2006
• 19 Strobl FF, Brechtel K, Schmehl J. et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013; 20: 699-706
• 20 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-848
• 21 Belch J, MacCuish A, Campbell I. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
• 22 Soejima H, Morimoto T, Saito Y. et al. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb Haem 2010; 104: 1085-1088
• 23 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800
• 24 Bonaca MP, Bhatt DL, Storey RF. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 2719-2728
• 25 Jones WS, Baumgartner I, Hiatt WR. et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017; 135: 241-250
• 26 Moll F, Baumgartner I, Jaff M. et al. Edoxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: Results of the ePAD trial. J Endovasc Ther 2018; 25: 158-168
• 27 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330
• 28 Anand SS, Bosch J, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229
• 29 Anand SS, Caron F, Eikelboom JW. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol 2018; 71: 2306-2315
• 30 Bonaca MP, Gutierrez JA, Creager MA. et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133: 997-1005
• 31 Capell WH, Bonaca MP, Nehler MR. et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J 2018; 199: 83-91
• 32 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004
• 33 Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351
• 34 The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-821
• 35 Antithrombotic Trialistsʼ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
• 36 Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 815-843
• 37 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Eng J Med 2006; 354: 1706-1717
• 38 Behrendt CA, Härter M, Kriston L. et al. IDOMENEO – Ist die Versorgungsrealität in der Gefäßmedizin Leitlinien- und Versorgungsgerecht? Ein Projekt zur Qualitätsentwicklung am Beispiel der peripheren arteriellen Verschlusskrankheit. Gefäßchirurgie 2017; 22: 41-47